Evidence map›Paper›PMID 41121782›Full record

ArticleThe Prostate2026

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer.

Taketo Kawai, Kazuki Maki, Satoru Taguchi, Yoichi Fujii, Takehiro Tanaka, Jimpei Miyakawa, Jun Kamei, Shigenori Kakutani, Aya Niimi, Daisuke Yamada and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Taketo KawaiDepartment of Urology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan.ORCID https://orcid.org/0000-0002-7279-2874
Kazuki MakiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Satoru TaguchiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1291-4294
Yoichi FujiiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takehiro TanakaDepartment of Pharmacy, the University of Tokyo Hospital, Tokyo, Japan.
Jimpei MiyakawaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Jun KameiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shigenori KakutaniDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Aya NiimiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Daisuke YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yuta YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tappei TakadaDepartment of Pharmacy, the University of Tokyo Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-3868-9320
Tohru NakagawaDepartment of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

backgroundCabazitaxel is a taxane agent associated with fewer symptomatic adverse events than docetaxel in treating castration-resistant prostate cancer (CRPC), yet it is typically reserved for post-docetaxel failure. This study assessed whether early switching from docetaxel to cabazitaxel could improve clinical outcomes.

methodsBeginning in 2019, a treatment approach was adopted wherein patients with CRPC were switched to cabazitaxel after three cycles of docetaxel, regardless of response. Patients who initiated docetaxel between February 2019 and March 2022 were classified as the switch group, while those who started between September 2014 and February 2019 were designated as the historical non-switch group. Chemotherapy duration, number of chemotherapy cycles, and adverse events were compared. Progression-free survival (PFS), time to failure of both taxanes, and overall survival (OS) were analyzed using propensity score matching.

resultsThe switch and non-switch groups included 36 and 37 patients, respectively. The switch group received significantly more chemotherapy cycles (p = 0.043) and had a longer cumulative chemotherapy duration (p = 0.035), even when including chemotherapy administered in subsequent lines. The cumulative incidence of peripheral neuropathy was significantly lower in the switch group (p = 0.037). Within the switch group, symptomatic adverse events, including fatigue, anorexia, and alopecia, were significantly reduced after switching to cabazitaxel. PFS was significantly prolonged in the switch group (p = 0.002), although time to failure of both taxanes and OS did not differ significantly between groups.

conclusionsEarly switching to cabazitaxel after three cycles of docetaxel may reduce symptomatic adverse events, including peripheral neuropathy, while enabling longer chemotherapy exposure and improved PFS in patients with CRPC.

Indexed as

Antineoplastic AgentsDocetaxelDrug SubstitutionProstatic Neoplasms, Castration-ResistantTaxoidsAgedAged, 80 and overHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntineoplastic AgentscabazitaxelDocetaxelTaxoidscabazitaxelcastration‐resistant prostate cancerdocetaxelearly switchingperipheral neuropathy

Identifiers

PMID41121782
PMCPMC12789904

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.